ARTICLE | Product Development
AstraZeneca impresses with resistant hypertension data at AHA 2025
Plus: Repairon’s tissue engineering for heart repair, and more
November 12, 2025 2:26 AM UTC
The 2025 American Heart Association Scientific Session in New Orleans this week featured full data from AstraZeneca’s Phase III trial in resistant hypertension that exceeded analyst expectations and a new readout from Repairon’s iPSC-derived human myocardium transplants.
AstraZeneca plc (LSE: AZN; NASDAQ: AZN) first announced top-line results from the Phase III Bax24 trial of baxdrostat in July, reporting that the ALDOS inhibitor significantly reduced ambulatory 24-hour average systolic blood pressure (SBP) versus placebo over 12 weeks in patients with resistant hypertension...